Xuekun Ren

Dr. Xuekun Ren


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YSYangguang Su
Yangguang Su
YWYing Wang
Ying Wang
ZQZhuo Qu
Zhuo Qu
JLJiaxin Liu
Jiaxin Liu
XRXuekun Ren
Xuekun Ren
Xiujie ChenXiujie Chen
Xiujie Chen
Introduction: Target therapy for cancer cell mutation has brought attention to several challenges in clinical applications, including limited therapeutic targets, less patient benefits, and susceptibility to acquired due to their clear biological mechanisms and high specificity in targeting cancers with specific mutations. However, the identification of truly lethal synthetic lethal therapeutic targets for cancer cells remains uncommon, primarily due to compensatory mechanisms.Methods: In our pursuit of core therapeutic targets (CTTs) that exhibit extensive synthetic lethality in cancer and the corresponding potential drugs, we have developed a machine-learning model that utilizes multiple levels and dimensions of cancer characterization. This is achieved through the consideration of the transcriptional and post-transcriptional regulation of cancer-specific genes and the construction of a model that integrates statistics and machine learning. The model incorporates statistics such as Wilcoxon and Pearson, as well as random forest. Through WGCNA and network analysis, we identify hub genes in the SL network that serve as CTTs. Additionally, we establish regulatory networks for non-coding RNA (ncRNA) and drug-target interactions.Results: Our model has uncovered 7277 potential SL interactions, while WGCNA has identified 13 gene modules. Through network analysis, we have identified 30 CTTs with the highest degree in these modules. Based on these CTTs, we have constructed networks for ncRNA regulation and drug targets. Furthermore, by applying the same process to lung cancer and renal cell carcinoma, we have identified corresponding CTTs and potential therapeutic drugs. We have also analyzed common therapeutic targets among all three cancers.Discussion: The results of our study have broad applicability across various dimensions and histological data, as our model identifies potential therapeutic targets by learning multidimensional complex features from known synthetic lethal gene pairs. The incorporation of statistical screening and network analysis further enhances the confidence in these potential targets. Our approach provides novel theoretical insights and methodological support for the identification of CTTs and drugs in diverse types of cancer.

9 September 2009 in Information Sciences
Verified
Journal Article
Closed access
CWCongxin Wu
Congxin Wu
HLHongliang Li
Hongliang Li
XRXuekun Ren
Xuekun Ren

1 March 2010 in Fuzzy Sets and Systems
Verified
Journal Article
Closed access
XRXuekun Ren
Xuekun Ren
Chong WuChong Wu
Chong Wu
CWCongxin Wu
Congxin Wu

14 February 2013 in International Journal of Theoretical Physics
Verified
Journal Article
Closed access
PDF file
XRXuekun Ren
Xuekun Ren
Hsien-Chung WuHsien-Chung Wu
Hsien-Chung Wu

14 July 2024 in Heliyon
Verified
Journal Article
Open access
YWYing Wang
Ying Wang
YSYangguang Su
Yangguang Su
KZKairui Zhao
Kairui Zhao
DHDiwei Huo
Diwei Huo
ZDZhenshun Du
Zhenshun Du
DZDenan Zhang
Denan Zhang
At the beginning of the "Disease X" outbreak, drug discovery and development are often challenged by insufficient and unbalanced data. To address this problem and maximize the information value of limited data, we propose a drug screening model, LGCNN, based on convolutional neural network (CNN), which enables rapid drug screening by integrating features of drug molecular structures and drug-target interactions at both local and global (LG) levels. Experimental results show that LGCNN exhibits better performance compared to other state-of-the-art classification methods under limited data. In addition, LGCNN was applied to anti-SARS-CoV-2 drug screening to realize therapeutic drug mining against COVID-19. LGCNN transcends the limitations of traditional models for predicting interactions between single drug targets and shows new advantages in predicting multi-target drug-target interactions. Notably, the cross-coronavirus generalizability of the model is also implied by the analysis of targets, drugs, and mechanisms in the prediction results. In conclusion, LGCNN provides new ideas and methods for rapid drug screening in emergency situations where data are scarce.

13 June 2026 in Scientific Reports
Verified
Journal Article
Open access
ZDZhenshun Du
Zhenshun Du
ZWZhiju Wang
Zhiju Wang
YCYu Chen
Yu Chen
BLBoyou Li
Boyou Li
XWXin Wan
Xin Wan
DZDenan Zhang
Denan Zhang
The current reliance on wet-lab experiments for evaluating the efficacy and adverse effects of natural products remains a major obstacle in new drug discovery. We propose KAN-PROSPECT, a novel deep learning framework that integrates transfer learning with Kolmogorov-Arnold Networks (KAN). This model can simultaneously predict the efficacy and adverse effects of natural products based solely on molecular SMILES representations, thereby addressing the limited generalizability of existing models in predicting these aspects for natural products. Beyond methodological advances, KAN-PROSPECT also contributes to more sustainable and resource-efficient drug discovery. Leveraging a cross-modal transfer learning strategy pretrained on approximately 3,800 drugs and fine-tuned on 400 natural products, KAN-PROSPECT consistently outperforms baseline models in dual-label prediction tasks. Notably, it demonstrates exceptional robustness in addressing data scarcity, excelling particularly in few-shot and zero-shot scenarios. Through the transfer learning strategy, the model partially alleviates the data scarcity issue commonly encountered in natural product prediction tasks. In addition, the incorporation of KAN layers enhances the ability to model complex nonlinear relationships between molecular structures and associated pharmacological or adverse reaction profiles, contributing to improved predictive performance. Furthermore, the framework demonstrates strong generalization ability, enabling high-accuracy predictions for the efficacy and adverse effects of entirely new natural products. KAN-PROSPECT was further applied to comprehensively predict natural products from the MEC and NPASS databases, with Icaritin from Epimedium used as a representative case study. Overall, KAN-PROSPECT is the first framework to unify transfer learning with the KAN architecture for dual-label prediction of natural products, showing great potential for large-scale bioactivity and toxicity prediction, new drug development, and drug repositioning of natural products.